The Semaglutide peptide has emerged as a compelling subject in biochemical and physiological research due to its potential ...

Dr. Lily Ackermann discussed inpatient diabetes care, focusing on real-world decisions and personalized treatment using ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

"Technosphere insulin has a unique delivery method, bioavailability, and pharmacodynamics leading to a very different clinical effect per unit compared to rapid-acting analogs." ...

With insulin analogs, the currently dominant category, the most striking factor is that nearly 90% of the insulin analogs that have been completely discontinued in the U.S. remain available in Europe.

A study has found that two shots of insulin (basal insulin analog), though higher in dose, is marginally better than a single shot (premixed insulin) in lowering HbA1c (glycated haemoglobin).

In adjusted multivariable analyses, significantly lower proportions of the analog than human insulin group experienced major adverse cardiovascular events (MACE, 26.8% vs 35.9%), hospitalization ...

Modernizing insulin Viewing insulin as a single chemical entity rather than a heterogenous extract proved essential for radically improving its potential as a drug. Scientists could apply rules from ...

Insulin analogs, which are synthetic versions of insulin, control blood sugar better than so-called human insulin, and represent more than 90% of the market, according to the American Action Forum ...

We expect to follow this up with launches of insulin analogues like Glargine, Aspart and Lispro and GLP-1 agonists like Liraglutide. We target to take a 10 per cent market share in this segment ...